Mirvetuximab soravtansine

ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Exercise, Attention, Floor, File, The 8th Floor, Telephone, Cancer, Guggenheim, ImmunoGen, IMGN, Mirvetuximab soravtansine, Sale, Public expenditure, Goldman Sachs, Prospectus, Jefferies Group, Madison Avenue, Security (finance), Spacecraft, Guggenheim Partners

The shares of common stock were sold at a price of $12.50 per share before underwriting discounts and commissions.

Key Points: 
  • The shares of common stock were sold at a price of $12.50 per share before underwriting discounts and commissions.
  • All of the shares of common stock in the offering were sold by ImmunoGen.
  • The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) were $373.8 million.
  • Jefferies, Goldman Sachs & Co. LLC, and Guggenheim Securities acted as joint book-running managers for the offering.

Shattuck Labs Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
Mirvetuximab soravtansine, Completeness, TP53, Macrophage, Neoplasm, Clinical trial, Cancer, Pharmacokinetics, Acute myeloid leukemia, ASCO, AML, Azacitidine, Patient, Autoimmune disease, Safety, Pharmaceutical industry, PROC

AUSTIN, TX and DURHAM, NC, May 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended March 31, 2023, and provided recent business highlights.

Key Points: 
  • Both expansion cohorts are expected to begin enrollment in the third quarter of 2023, and we now expect to complete enrollment in both expansion cohorts during the second half of 2023.
  • Research and Development (R&D) Expenses: R&D expenses were $16.7 million for the quarter ended March 31, 2023, as compared to $19.2 million for the quarter ended March 31, 2022.
  • General and Administrative (G&A) Expenses: G&A expenses were $5.1 million for the quarter ended March 31, 2023, as compared to $5.0 million for the quarter ended March 31, 2022.
  • Shattuck believes its cash and cash equivalents and investments will be sufficient to fund its operations through year-end 2024, beyond results from its Phase 1 clinical trials of SL-172154.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, CT, Senior, Fallopian tube cancer, Overalls, Survival, Cancer, Fallopian tube, Gynecologic Oncology (journal), Peritonitis, ImmunoGen, Mirvetuximab soravtansine, IMGN, Associate, ASCO, Bevacizumab, American Society of Clinical Oncology, MD, Patient, University, Randomness, Clinical research, University of Oklahoma, Annual general meeting, Spacecraft, GOG, Society, Safety, Birth control, Maintenance

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.

Key Points: 
  • "We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.
  • "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."
  • Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs.
  • ImmunoGen will present two additional trial-in-progress posters at ASCO.

ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock

Retrieved on: 
Friday, May 5, 2023
General Health, Pharmaceutical, Health, Oncology, Exercise, Attention, Floor, File, The 8th Floor, Telephone, Cancer, Guggenheim, IMGN, Mirvetuximab soravtansine, Sale, Public expenditure, Goldman Sachs, Prospectus, Jefferies Group, ImmunoGen, Madison Avenue, Security (finance), Spacecraft, Guggenheim Partners

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions.

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 26,000,000 shares of its common stock at a price of $12.50 per share, before underwriting discounts and commissions.
  • The offering is expected to close on or about May 9, 2023, subject to satisfaction of customary closing conditions.
  • ImmunoGen also granted the underwriters a 30-day option to purchase up to an additional 3,900,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock in the offering are to be sold by ImmunoGen.

ImmunoGen Announces Proposed Public Offering of Common Stock

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Attention, Floor, File, The 8th Floor, Telephone, Cancer, Guggenheim, IMGN, Mirvetuximab soravtansine, Sale, Public expenditure, Goldman Sachs, Prospectus, Jefferies Group, ImmunoGen, Madison Avenue, Security (finance), Spacecraft, Guggenheim Partners

ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • ImmunoGen also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the number of shares of common stock offered in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the shares of common stock to be sold in the offering are to be offered by ImmunoGen.
  • There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Jefferies, Goldman Sachs & Co. LLC, and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer

Retrieved on: 
Wednesday, May 3, 2023
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Topotecan, Bevacizumab, Progression-free survival, Neoplasm, OS, Cancer, Paclitaxel, IC, Gynecologic Oncology (journal), Associate, PFS, IMGN, Mirvetuximab soravtansine, Ventana, Patient, Risk, University, Clinical research, University of Oklahoma, Spacecraft, GOG, MAA, Ovarian cancer, PARP, Death, ORR, Safety, Disease, Pharmaceutical industry

FRα status is a 'must know' for all ovarian cancer patients and, for those with platinum-resistant disease who test positive, I believe ELAHERE should be their first treatment option."

Key Points: 
  • FRα status is a 'must know' for all ovarian cancer patients and, for those with platinum-resistant disease who test positive, I believe ELAHERE should be their first treatment option."
  • MIRASOL (NCT04209855) is a randomized Phase 3 trial of ELAHERE versus investigator's choice (IC) of single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan).
  • "Importantly, ELAHERE is the first drug to show an overall survival benefit in this patient population.
  • These results are remarkable and we extend our appreciation to all of the patients and physicians who participated in MIRASOL.

ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results

Retrieved on: 
Friday, April 28, 2023
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Biologics license application, Capital expenditure, Society, SGO, ASH, Senior, Progression-free survival, Marketing, European Medicines Agency, Survival, Clinical trial, Cancer, Gynecologic Oncology (journal), György Enyedi (geographer), Society of Gynecologic Oncology, NSCLC, Lung cancer, PFS, Mirvetuximab soravtansine, Gilead, Eli Lilly, EMA, Acute myeloid leukemia, PROC, AML, Azacitidine, PIN, Huadong Medicine, Pharmakon—Danish College of Pharmacy Practice, Patient, National Medical Products Administration, Annual general meeting, ImmunoGen, Vertex Pharmaceuticals, ADC, Spacecraft, MAA, Research, FDA, Ovarian cancer, LP, BLA, NMPA, Medicine, Vaccine, Management, Pharmaceutical industry, Mobile phone, Vertex

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2023.
  • Research and development expenses rose to $51.6 million for the quarter ended March 31, 2023 compared to $44.3 million for the quarter ended March 31, 2022.
  • Selling, general and administrative expenses were $40.0 million for the quarter ended March 31, 2023 compared to $16.6 million for the quarter ended March 31, 2022.
  • ImmunoGen had $201.2 million in cash and cash equivalents as of March 31, 2023, compared with $275.1 million as of December 31, 2022.

ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer

Retrieved on: 
Monday, April 24, 2023
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, BS, Senior, Hereditary angioedema, Takeda, Cancer, Babson College, Atopic dermatitis, MBA, ImmunoGen, IMGN, Mirvetuximab soravtansine, HAE, Acquisition, Patient, Physician, Executive Committee, ADC, Prurigo nodularis, Spacecraft, Rare, Ovarian cancer, Neurology, Takeda Pharmaceutical Company, Vaccine, EU

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
  • "We are excited to welcome Isabel to ImmunoGen's Executive Committee to lead our best-in-class commercial organization at this important moment for the company.
  • Before Shire, she worked in commercial, business strategy, and product launch positions at Forest Labs, Bionevia Pharmaceuticals, and Sunovion Pharmaceuticals.
  • "I am delighted to join ImmunoGen during this exciting time in its evolution into a commercial organization," said Ms. Kalofonos.

ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting

Retrieved on: 
Saturday, March 25, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Sequence, Bevacizumab, Society, SGO, Survival, Cancer, Gynecologic Oncology (journal), Mirvetuximab soravtansine, Society of Gynecologic Oncology, ImmunoGen, IMGN, Annual general meeting, Spacecraft, Pharmaceutical industry, Medical imaging, Patient

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of mirvetuximab soravtansine in patients with folate receptor alpha-high platinum-resistant ovarian cancer who had been previously treated with bevacizumab will be presented by Dr. Robert Coleman in a plenary session on Saturday, March 25, at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting in Tampa, Florida.
  • Title: Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Evaluation of Sequence of Therapy on Anti-Tumor Activity in the SORAYA Study

Shattuck Labs Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, February 23, 2023
Clinical trial, ARC, Autoimmune disease, Safety, ImmunoGen, Cancer, CD47, Patient, CD40, Fallopian tube cancer, Mirvetuximab soravtansine, Lutheran Student Fellowship, DRS, Growth, Therapy, AML, PS2, Macrophage, TP53, Completeness, CSO, Neoplasm, Pharmacokinetics, Pharmaceutical industry, Azacitidine

“During the fourth quarter of 2022, we continued to focus on clinical execution to position ourselves for key clinical data readouts for SL-172154 in 2023.

Key Points: 
  • “During the fourth quarter of 2022, we continued to focus on clinical execution to position ourselves for key clinical data readouts for SL-172154 in 2023.
  • We look forward to benefiting from the expertise of these scientific program leaders as we continue our momentum in 2023.
  • Dr. Fromm joined Shattuck Labs in 2017 and is one of its scientific co-founders.
  • This increase was primarily driven by a litigation settlement of $1.4 million and increases in personnel-related and other operating costs.